Bli medlem
Bli medlem

Du är här


Medivir: Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim

Stockholm, Sweden - Medivir AB (OMX: MVIR) today announces that it has
entered a license agreement with Boehringer Ingelheim International
GmbH for exclusive, global rights to a drug program for the treatment
and prevention of Respiratory Syncytial Virus (RSV) infection.

"RSV is respiratory pathogen that can cause life-threatening
infections, especially in children, the elderly and the
immunocompromised. It is a major, underserved disease area today,
with no effective treatment available" said Maris Hartmanis,
Medivir's CEO. "The in-licensing of this program illustrates
Medivir's strategic intent to enhance its R&D pipeline with
high-value, commercial opportunities."

The program includes novel compounds that inhibit the RSV fusion
protein, which is a key mediator of viral entry into host cells and a
target for new medicines. "We are very pleased to have secured this
program from Boehringer Ingelheim and to have the opportunity to
build upon the impressive research already conducted" said Richard
Bethell Medivir's EVP, Discovery Research. "We can now look forward
to advancing potential new drugs for the benefit of vulnerable

Under the terms of the agreement Medivir receives an exclusive, global
license to research, develop, manufacture and commercialise RSV drugs
resulting from Boehringer Ingelheim's program. Boehringer Ingelheim
receives an upfront payment and future success milestones as well as
royalties on sales.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

About RSV
Human respiratory syncytial virus is the main viral cause of
respiratory tract infection in infants, the elderly and the severely
immunocompromised. Almost all children will have been infected with
RSV by the time of their second birthday. It has been estimated that
RSV resulted in around 33.8 million lower respiratory tract
infections in children younger than 5 years in 2005, with 3.4 million
requiring hospitalization and between 66,000 and 199,000 child deaths
(Nair et al. 2010). Today only one drug is approved for therapeutic
use - ribavirin - but its use is limited by a complex administration
procedure, limited efficacy, high cost and toxic side effects. A
humanised monoclonal antibody is available for prophylatic use, but
it is approved only for prevention of RSV infection in infants that
are at very high risk of serious lower respiratory tract disease
following infection by RSV. Patients urgently need new, safe and
effective drug options for the treatment and prevention of RSV

About Medivir
Medivir is an emerging and profitable research-based pharmaceutical
company with an established marketing and sales organisation in the
Nordics with a broad portfolio of prescription pharmaceuticals.
Medivir receives royalty from Johnson & Johnson global sales of the
hepatitis C pharmaceutical Olysio. In addition, revenues for sales of
Olysio in the Nordic region is generated through the companies own
sales and marketing organisation. Medivir's research and development
portfolio of pharmaceuticals is based on the company's expertise in
polymerase and protease drug targets for different disease areas. The
company's current research and development is focused on infectious
diseases, bone related disorders, neuropathic pain and oncology.
Medivir is listed on the Nasdaq OMX Mid-Cap list.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.